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Kaposi's sarcoma-associated herpesvirus (KSHV) is a
human lymphotropic gammaherpesvirus and associated
with Kaposi sarcoma as well as two B cell lymphoprolifer-
ative disorders: primary effusion lymphoma (PEL) and
multicentric Castleman disease. We reported that the
KSHV latency-associated nuclear antigen (LANA) trans-
genic mice developed splenic follicular hyperplasia and
showed increased germinal center formation. Here we
report that the KSHV LANA-induced B cell activation is
CD19 dependent and LANA restores the marginal zone
defect in CD19-/- mice. To test KSHV latent genes' role in
viral lymphomagenesis, we generated mice expressing all
KSHV latency-associated genes. All of the transgenic mice
induced mature B cell activation. Further characterization
of the mice expressing all KSHV latency-associated genes
is currently underway.
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